ERBB2 and cancer: In particular, the combination of the PD-1 inhibitor pembrolizumab plus margetuximab has shown promising levels of activity in a phase Ib-II trial in HER2-positive GCs and GEJ cancers, with an ORR of 35.7% and a DCR of 67.9% in the HER2 3+ and PD-L1 positive patient population [40].